Truist Securities analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Sell with a price target of $8.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE